CC-97540 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Secondary Progressive Multiple Sclerosis (SPMS). According to GlobalData, Phase I drugs for Secondary Progressive Multiple Sclerosis (SPMS) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CC-97540’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CC-97540 overview
CC-97540 is under development for the treatment of relapse and refractory Non-Hodgkin lymphoma, diffuse large B-cell lymphoma, marginal zone B-cell lymphoma, primary mediastinal B-cell lymphoma, severe refractory systemic lupus erythematosus, relapsing multiple sclerosis (RMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS) and grade 3b follicular lymphoma. It is administered by intravenous route. The therapeutic candidate comprises of T-cells genetically engineered to express chimeric antigen receptor targeting cells expressing CD19.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.
For a complete picture of CC-97540’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
